We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Defers Action on BeiGene/Novartis Checkpoint Inhibitor, Citing Inspection Problems
FDA Defers Action on BeiGene/Novartis Checkpoint Inhibitor, Citing Inspection Problems
The FDA has deferred action on BeiGene’s Biologics License Application (BLA) for the monoclonal antibody tislelizumab for esophageal cancer, saying the agency has been unable to conduct required inspections in China due to COVID-19-related travel restrictions.